Quantification of plasma Epstein–Barr virus DNA for assessing treatment response in a patient with plasmablastic lymphoma
Plasmablastic lymphoma (PBL) is a rare and aggressive type of non-Hodgkin's lymphoma. It typically expresses plasma cell-associated markers, but with weak or absent expression of pan B cell markers (CD19, CD20). Ninety percent of the patients are human immunodeficiency virus (HIV) positive, and most patients have advanced diseases . The pathogenesis is Epstein–Barr virus (EBV) related in most patients [2, 3]. Treatment of PBL has consisted of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP); hyper-CVAD chemotherapy ; or local excision followed by radiation. The clinical course is usually aggressive, and most of the patients die in the first year after diagnosis .
In other EBV-associated lymphomas such as Hodgkin's lymphoma and nasal NK/T cell lymphoma, circulating EBV DNA has been reported to be a useful biomarker for monitoring response to chemotherapy treatment [6, 7, 8]. The use of circulating EBV DNA in PBL was not studied. In this report,...
KeywordsRheumatic Heart Disease Latent Membrane Protein Chop Chemotherapy Plasmablastic Lymphoma Tuberculosis Lymphadenitis
The authors would like to thank Dr WY Au for the assay of the plasma EBV DNA.
Conflicts of interest
The authors declare no conflict of interest.